title: Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
abstract: OBJECTIVE
  To evaluate preoperative concomitant chemoradiation using cisplatin plus docetaxel followed by consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Medical records of patients with locally advanced unresectable NSCLC (stage IIIA and IIIB) treated with concomitant chemoradiotherapy using cisplatin + docetaxel combination followed by consolidation chemotherapy were retrospectively evaluated. All the patients were consecutively treated. Chemotherapy consisted of weekly cisplatin 20 mg/m(2) and docetaxel 20 mg/m(2) during radiotherapy. Radiotherapy dose was 58-66 Gy given in 2 Gy fractions, 5 days per week. The patients were subsequently referred to surgery if adequately downstaged. Consolidation chemotherapy using cisplatin and docetaxel both at doses 75 mg/m(2) every 3 weeks followed local therapy in all patients.
  
  
  RESULTS
  A total of 54 patients were evaluated (49 males, 5 females with a median age of 58 years; 41 [75.9%] stage IIIB and 13 [24.1%] IIIA). Twelve patients (22.2%) achieved pathologic complete response and 20 (37%) partial response. Downstaging was possible in 32 patients (59.3%). Twenty-six patients (48.1%) were operated after concomitant chemoradiotherapy (pneumonectomy [n = 2], lobectomy [n = 12], and wedge resection [n = 12]). Toxicity was tolerable. Median progression-free survival and overall survival (OS) for the entire cohort were 14 and 22 months, respectively. In resected patients (n = 26), median PFS and OS have not been reached with a median follow-up duration of 24 months.
  
  
  CONCLUSIONS
  Preoperative concomitant chemoradiation using weekly cisplatin and docetaxel followed by surgery and consolidation chemotherapy is effective and well tolerated in patients with unresectable locally advanced NSCLC.
authors.affiliation: Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
authors.forename: Ali Osman
authors.initials: AO
authors.lastname: Kaya
authors.forename: Suleyman
authors.initials: S
authors.lastname: Buyukberber
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Muge
authors.initials: M
authors.lastname: Akmansu
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Banu
authors.initials: B
authors.lastname: Ozturk
authors.forename: Emel
authors.initials: E
authors.lastname: Yaman
authors.forename: Mehmet Emin
authors.initials: ME
authors.lastname: Kalender
authors.forename: Okan
authors.initials: O
authors.lastname: Orhan
authors.forename: Deniz
authors.initials: D
authors.lastname: Yamac
authors.forename: Aytug
authors.initials: A
authors.lastname: Uner
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011013:Pneumonectomy; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage* / Q000009:adverse effects; D011879:Radiotherapy Dosage; D043823:Taxoids / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin